Plain-English translation of NCT06138275 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called in patients with advanced multiple myeloma (a blood cancer) who have already received CAR-T cell therapy as their primary treatment. is a special type of immune protein that works by connecting your T-cells (infection-fighting cells) directly to cancer cells, teaching your immune system to destroy them. The trial will follow about 32 patients to see whether this medication can help prevent the cancer from coming back.
Multiple myeloma can come back even after successful CAR-T cell therapy, and patients with very advanced disease have few remaining treatment options. This trial is investigating whether adding this medication after CAR-T therapy might help keep the cancer under control longer and give patients more time before needing additional treatments.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication under your skin at regular study visits over a 6-month period. During the first cycle (first 4 weeks), you'll have injections on specific days; in the second cycle, you'll have fewer injections; and in later cycles, you'll receive injections twice per month. You'll be followed closely with blood tests and disease monitoring visits to track how well the treatment is working and watch for any side effects, continuing until your disease worsens or you need other treatment.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States